shmewski Posted - 2 days ago

$MBRX buyout

sprinx Posted - 2 days ago

$MBRX

GiraldoFetz Posted - 2 days ago

$MBRX almost showtime....I see shit-for-brains made another appearance, eh...good for him. 📈📈📈📈🚀🌙⏰️

jkgyuool Posted - 2 days ago

$MBRX Really really pathetic volume. Wally- just sell the company already and let us end this misery of an investment whether break even or down. So sad this is happening. I have no trust in leadership. Vote them all out

Stock_Titan Posted - 3 days ago

$MBRX Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress https://www.stocktitan.net/news/MBRX/moleculin-abstract-accepted-for-poster-presentation-at-the-european-lo7n39trhbz4.html

jkgyuool Posted - 3 days ago

$MBRX Obviously not much volume so far after good news. 2k shares, unbelievable. Either no one cares, no one trusts, or both. So sad

GiraldoFetz Posted - 4 days ago

$MBRX go easy, girl 📈⏰️

GiraldoFetz Posted - 4 days ago

$MBRX there we go...📈📈📈⏰️ Is buddy-guy still around spewing his "ThiS sTonK OnLy go3s DoWn" garbage... 😅🤣😂

TraderJay85 Posted - 4 days ago

$MBRX added 4.84

Wolfpackcommunity Posted - 4 days ago

$MBRX news

HorsePicks Posted - 4 days ago

$MBRX Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Stock_Titan Posted - 4 days ago

$MBRX Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) https://www.stocktitan.net/news/MBRX/moleculin-announces-commencement-of-nih-funded-phase-2-clinical-ed9nehn14f63.html

Zdxss Posted - 4 days ago

$MBRX I think that Mr. Wali is exaggerating and his estimate of a stock is unrealistic...unless there is information that he is hiding and is waiting for the appropriate time to announce it, which made him estimate the share price at $600.

ezMoney001 Posted - 4 days ago

$MBRX Hey did you hear , Wally places a conservative estimate on the stock at 600 USD per share !!! .... I guess that assumes he pays for the Phase 2 and 3 trials with the remaining 16 million in cash ,,,,, Magic !!!

123rickiek Posted - 4 days ago

$MBRX View Filing Data for SEC filing 0001437749-24-016631 https://s3.amazonaws.com/sec.irpass.cc/2705/0001437749-24-016631.htm

bilskybill Posted - 4 days ago

$MBRX Anyone actually believe that there is 21,273 actual traders watching this manipulated corrupt stock???

bilskybill Posted - 5 days ago

$MBRX Which of you traders will be visiting Kemp and his gang of thieves in prison after the SEC wakes up to have a look here?

Roy111 Posted - 5 days ago

$MBRX

Zdxss Posted - 6 days ago

$MBRX No one is waiting for the drug to be approved. We are waiting for big companies to buy the medicine or acquire the company

MiltonMilkyMilkovich Posted - 6 days ago

$MBRX the data is compelling no one else comes close

MiltonMilkyMilkovich Posted - 6 days ago

$MBRX Klemp: ”big pharma is already looking at us” hmmm 🤷‍♂️

Fitz54 Posted - 6 days ago

$MBRX no NDA submission until 2027 they are going to need tons of funding (dilution) imo. Only one more quarter of cash

DonCorleone77 Posted - 6 days ago

$MBRX Moleculin Biotech reports Q1 EPS ($2.02) vs. ($4.13) last year As of March 31, the company had cash and cash equivalents of $16.8M and believes that this cash is sufficient to meet its projected operating requirements, which includes the company's current Phase 1B/2 clinical programs and preparations for future clinical trials, into Q4 2024. "We recently hosted a virtual AML Clinical Day featuring renowned KOLs, Dr. Martin Tallman and Dr. Michael Andreeff. It was great to hear their support of and thoughts on Annamycin's recent developments in AML. You can hear that discussion here. Combined with the encouraging Annamycin data demonstrated to date and the positive feedback from the KOLs, we continue to believe that our results in 2nd line subjects fill a significant unmet need. We believe this is supported by the exceptional CRc rate demonstrated by AnnAraC in 2nd line patients, which substantially exceeds the performance reported by any drug currently approved in the U.S. for use in 2nd line AML. We believe we are well-positioned for a highly productive End of Phase 2 meeting with FDA to discuss our planned pivotal study of Annamycin for AML," commented CEO Walter Klemp.

Stock_Titan Posted - 6 days ago

$MBRX Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update https://www.stocktitan.net/news/MBRX/moleculin-reports-first-quarter-2024-financial-results-and-provides-s6onr8w562ka.html

bilskybill Posted - 6 days ago

$MBRX Another reverse split, then management bonuses? Seems real crooked to me. How do you all feel about it?

Blue_pineslapel Posted - 1 week ago

$MBRX

Blue_pineslapel Posted - 1 week ago

$MBRX are they releasing earnings

jkgyuool Posted - 1 week ago

$MBRX A pop to you Giraldo is $8-9. To most of us we need $25 + to break even.

GiraldoFetz Posted - 1 week ago

$MBRX just here for the pop...matter of time.

sprinx Posted - 1 week ago

$MBRX Everything is falling into place here